Caris Life Sciences, Inc.
No SEC Form 4 filings for $CAI in the last 30 days.
Caris Life Sciences (NASDAQ:CAI) shares rose up to about 21.6% after its Q2 results. The company cut net loss to $637,000 and increased revenue 45% to $263.7 million, driven by a 55% jump in molecular profiling services. It guided 2026 revenue of $1.03B to $1.04B and noted 59,200 clinical cases. Hedge fund holdings fell in Q1.
Caris Life Sciences (NASDAQ:CAI) shares rose up to 21.58% after Q2 results. The company cut net loss attributable to shareholders to $637,000 from $517.2M, while revenue rose 45% to $263.7M. Molecular profiling services revenue increased 55% to drive growth. Caris forecasts 2026 revenue of $1.03B-$1.04B and 26.8%-28% growth, and reaffirmed therapy selection volume growth guidance.
Caris Life Sciences said a study in Cancer Research Communications used a multimodal deep learning model combining digitized H&E pathology images and clinical data to estimate late distant recurrence risk in HR+ early breast cancer. It was trained on 2,271 NSABP B-42 patients and validated on 4,300 TAILORx specimens, showing about an 8% 10-year risk gap between model high and low groups and suggesting greater benefit from extended letrozole in high-risk patients.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CAI (Caris Life Sciences, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent CAI coverage spans earnings, financial news and technology.
Momentum is tied to whether Caris Detect uptake can sustain the newly guided revenue trajectory.
The article ties CAI’s post-earnings momentum to sustained demand for Caris Detect and updated 2026 revenue and therapy-selection growth guidance.
Caris Life Sciences said a study in Cancer Research Communications used a multimodal deep learning model combining digitized H&E pathology images and clinical data to estimate late distant recurrence risk in HR+ early breast cancer. It was trained on 2,271 NSABP B-42 patients and validated on 4,300 TAILORx specimens, showing about an 8% 10-year risk gap between model high and low groups and suggesting greater benefit from extended letrozole in high-risk patients.
Guidance raise plus record case volume and improved gross margin suggest accelerating fundamentals and potential upward repricing.
The trade setup is centered on MRD business timing and tissue/liquid test trend improvement relative to expectations.
alphai scores every news story that mentions CAI with an AI model for sentiment and relevance, and aggregates insider trades from Caris Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Caris Life Sciences (NASDAQ:CAI) shares rose up to about 21.6% after its Q2 results. The company cut net loss to $637,000 and increased revenue 45% to $263.7 million, driven by a 55% jump in molecular profiling services. It guided 2026 revenue of $1.03B to $1.04B and noted 59,200 clinical cases. Hedge fund holdings fell in Q1.
6 min readCaris Life Sciences (NASDAQ:CAI) shares rose up to 21.58% after Q2 results. The company cut net loss attributable to shareholders to $637,000 from $517.2M, while revenue rose 45% to $263.7M. Molecular profiling services revenue increased 55% to drive growth. Caris forecasts 2026 revenue of $1.03B-$1.04B and 26.8%-28% growth, and reaffirmed therapy selection volume growth guidance.
6 min readCaris Life Sciences said a study in Cancer Research Communications used a multimodal deep learning model combining digitized H&E pathology images and clinical data to estimate late distant recurrence risk in HR+ early breast cancer. It was trained on 2,271 NSABP B-42 patients and validated on 4,300 TAILORx specimens, showing about an 8% 10-year risk gap between model high and low groups and suggesting greater benefit from extended letrozole in high-risk patients.
4 min readCaris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical
6 min readInvesting.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min readInvesting.com reported Monday insider trading filings. Energizer (ENR): reporting owners bought 60,000 shares for about $1.23M at ~$20.20-$20.75. Gloo (GLOO): Grace & Mercy Foundation bought 923,076 shares for ~$3.00M. IPERIONX (IPX): CEO and chairman bought shares totaling about $2.38M. Arista (ANET): CEO sold 242,422 shares for ~$45.6M. Dell (DELL): Silver Lake sold about 124,598 shares for ~$58.1M.
4 min readHALBERT JON purchased 68,000 indirectly-held shares of Caris Life Sciences, Inc. (CAI) at $14.56 ($0.99M total) on 2026-05-15.
2 min readCaris Life Sciences (CAI) announced a $100 million share repurchase program. The article also discusses broader AI and robotics themes, citing remarks from Bill Gates, Larry Ellison/Oracle, and Warren Buffett, but it provides no additional CAI financial figures beyond the buyback size.
2 min readEd Yardeni of Yarden Research told CNBC’s “Squawk Box” that a June “swoon” after stronger-than-expected payrolls may have been limited to June 5, and he expects further upside in July. He cited SpaceX’s IPO as a positive sentiment signal and said S&P 500 firms are projected to grow earnings ~20% over seven quarters. The article also lists new stocks with claimed upside, including Caris Life Sciences’ $100m buyback authorization and Atour’s Q1 2026 revenue of RMB2.8b (+47.5% YoY).
7 min readCaris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cai-20260604 0002019410 FALSE 0002019410 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ FORM 8-K _______________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchang
3 min read
